PRESCRIBE MOTION AND RETURN TO A HEALTHIER LIFE.

DJO GLOBAL

December 2014
This presentation has been prepared by DJO Finance LLC, the public reporting subsidiary of DJO Global, Inc. (DJOFL). The information contained in this presentation is for information purposes only. The information contained in this presentation is not investment or financial product advice and is not intended to be used as the basis for making an investment decision. This presentation has been prepared without taking into account the investment objectives, financial situation or particular needs of any particular person.

No representation or warranty, expressed or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions and conclusions contained in this presentation. To the maximum extent permitted by law, none of DJOFL, its directors, employees or agents, nor any other person accepts any liability, including, without limitation, any liability arising out of fault or negligence for any loss arising from the use of the information contained in this presentation.

The historical and projected financial information in this presentation includes financial information that is not presented in accordance with generally accepted accounting principles (GAAP). Non-GAAP financial measures may be considered in addition to GAAP financial information, but should not be used as substitutes for the corresponding GAAP measures. Non-GAAP measures in this presentation may be calculated in a way that is not comparable to similarly titled measures reported by other companies.

This presentation includes “forward-looking statements” that reflect DJOFL’s current views and information currently available. This information is, where applicable, based on assumptions and analysis that DJOFL believes, as of the date hereof, provide a reasonable basis for the data contained herein. Forward-looking statements can generally be identified by the use of forward-looking words such as “may”, “will”, “would”, “could”, “expect”, “intend”, “plan”, “aim”, “estimate”, “target”, “anticipate”, “believe”, “continue”, “objectives”, “outlook”, “guidance” or other similar words, and include statements regarding DJOFL’s plans, strategies, objectives, targets and expected financial performance. Forward-looking statements include statements concerning our plans, objectives, goals, strategies, future events, capital expenditures, future results, our competitive strengths, our business strategy, the trends in our industry and the benefits of and the anticipated cost savings related to our recent acquisitions. These forward-looking statements involve known and unknown risks, uncertainties and other factors, many of which are outside the control of DJOFL and its officers, employees, agents or associates. Actual results, performance or achievements may vary materially from any projections and forward-looking statements and the assumptions on which those forward statements are based. Readers are cautioned not to place undue reliance on forward-looking statements as a predictor of future performance. These forward looking statements are within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act, and are intended to be covered by the safe harbors created thereby. Some of the factors that we believe could affect our results include the risks discussed in the “Risk Factors” section in DJOFL’s Annual Report on Form 10-K for the year ended December 31, 2013, filed on February 25, 2014 with the Securities and Exchange Commission. We caution you that in light of the risks and uncertainties described in this “Risk Factors” section, the matters referred to in the forward looking statements contained in this presentation may not in fact occur. There can be no assurance that the data contained herein is reflective of future performance to any degree. All information herein speaks only as of (1) the date hereof, in the case of information about DJOFL, or (2) the date of such information, in the case of information from persons other than DJOFL. DJOFL undertakes no duty to update or revise the information contained herein, publicly or otherwise. Forecasts and estimates regarding DJOFL’s industry and end markets are based on sources we believe to be reliable, however there can be no assurance these forecasts and estimates will prove accurate in whole or in part.
DJO Global

Headquarters
San Diego

Founded in 1978 in Carlsbad, CA

~5,400 employees in 27 countries

Orthopedic Focus

Unique strategy focusing on injury prevention, conservative treatment and rehabilitation

Innovator

Robust pipeline of products and solutions that are more cost effective and less invasive than most surgical or pharmaceutical alternatives

Privately Owned

Financial sponsor – The Blackstone Group

Mission

Solutions that keep people active
“Motion is Medicine”

Revenue and Adjusted EBITDA(1)

4.6% CAGR Net Sales (2011-2013)

<table>
<thead>
<tr>
<th>Year</th>
<th>Revenue</th>
<th>Adjusted EBITDA</th>
</tr>
</thead>
<tbody>
<tr>
<td>2011</td>
<td>$1,075</td>
<td>$264</td>
</tr>
<tr>
<td>2012</td>
<td>$1,129</td>
<td>$271</td>
</tr>
<tr>
<td>2013</td>
<td>$1,176</td>
<td>$264</td>
</tr>
<tr>
<td>LTM Q3-14</td>
<td>$1,216</td>
<td>$274</td>
</tr>
</tbody>
</table>

LTM Q3-14 Revenue by Segment

- Bracing and Vascular: 41%
- Recovery Sciences: 25%
- International: 26%
- Surgical Implant: 8%

DJO Global is at the Heart of Changing Healthcare

(1) Adjusted EBITDA for all periods presented excludes impact of non-recurring costs and other adjustments as permitted by Senior Secured Credit Agreement; excludes pre-acquisition EBITDA and future cost savings related to acquisitions.
## Attractive Industry Dynamics

- Large addressable markets
- Arthritis is a large market with 44 million patient suffers
- Diabetes is growing at 165% per year
- Growing “baby boomers” population with average life expectancy at 78 years old
- Conservative Care Mandates

## Key Competitive Advantages

- #1 in Orthopedic clinics
- #1 in Physical Therapy clinics
- #1 in Non-Operative Care
- #1 in 3rd Party Distribution
- #1 in Billing Private Insurance Companies and CMS
- Sole Source or Prime Vendor at All IDN’s and GPOs

## Key Growth Strategies

- Differentiated solutions that keep people moving
- Continuum of Care
- Sustainable innovation gap
- Automated back office and Doctor/Patient interfaces
Market Opportunity
DJO GLOBAL - HISTORIC ADDRESSABLE MARKETS

• DJO Global historically focused in **sports medicine** and **physical therapy** markets

• DJO Global has strong share in those markets

---

**Global Bracing & Supports Market** in Sports Medicine, Physical Therapy, Training Room, & Hospitals

**Global Recovery Sciences Market** in Physical Therapy & Pain Clinics

**Diabetic Footwear Market**

**Total Orthopedic Surgical Market**
DJO Opportunity

- **Total Elective Orthopedic Surgical Market**
  - $110M in 2014
  - DJO Growing 17%

- **MotionCare**
  - $35M in 2014
  - DJO Growing 28%

- **Consumer Market**
  - $10M in 2014
  - DJO Growing 16%
Over **44 million** patients in clinics with arthritis could benefit from our MotionCare protocol and products.

- **$26B** Motion Care Opportunity at $1,500 per patient

- **$17B** Total Orthopedic Surgical Market

1 – Estimated from $17B market at an ASP of $4,000
2 – According to Arthritis Foundation
3 – Estimated from 44M patients at $1,500/patient with 40% penetration
Patients seeking *preventative* or *conservative/non-surgical* care products

The consumer sports medicine market is nearly 7x the size of the professional sports medicine & physical therapy market

Orthopedic Surgeon

$3B$ Professional Market

Retail Channel

$20B$ Consumer Market
Orthopedic Implants

• Drive deep into large niche opportunities that are hard for the larger players to address

• Strategy successful in shoulders and minimally invasive hips

• The only company that can provide orthopedic care products from the onset of arthritis through surgical rehabilitation

Preventative
• Bracing
• TENS Pain Relief
• Muscle Stim

Surgical
• Implant
• DVT Prevention

Rehabilitation
• Bracing
• TENS Pain Relief
• Muscle Stim
• DVT Prevention

$17B
Competitive Advantages
Sustainable Innovation Gap

- Rapidly developing and launching differentiated solutions that help keep people moving
- Stay ahead of the competition
- Stronger pricing power
Leading Market Positions: Defensible, Comprehensive Product Offering

- Market leader in multiple market segments and product categories
- Established global presence with over 60 years of history in the physical therapy market and over 30 years of history in the orthopedics market
- Brand recognition and comprehensive product range promotes loyalty from prescribing physicians and physical therapists
- Low regulatory and technology substitution risk
<table>
<thead>
<tr>
<th>Customer Call Point</th>
<th>How we get there</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Orthopedic Surgeons</td>
<td>• DonJoy and Surgical Distributor Partners</td>
</tr>
<tr>
<td>• Podiatry</td>
<td>• Independent Sales Representatives</td>
</tr>
<tr>
<td>• Physical Therapy/ Chiropractic</td>
<td>• Direct Sales Representatives</td>
</tr>
<tr>
<td>• Spine Surgeons</td>
<td>• Telesales</td>
</tr>
<tr>
<td>• Athletic Trainers</td>
<td>• Custom Bracing and Equipment Fitters</td>
</tr>
<tr>
<td>• Primary Care</td>
<td>• Strong relationships through Business Development</td>
</tr>
<tr>
<td>• Pain Management</td>
<td></td>
</tr>
<tr>
<td>• Hospitals</td>
<td></td>
</tr>
<tr>
<td>• O&amp;P/ DME/ Pharmacy</td>
<td></td>
</tr>
<tr>
<td>• Retail</td>
<td></td>
</tr>
</tbody>
</table>
Competitive Advantages in Manufacturing, Distribution and R&D

- Main manufacturing facility in Tijuana, Mexico
- Culture of continuous improvement, driving company-wide productivity
- Efficient, automated distribution capabilities (24-72 hour delivery)
- Comprehensive mechanical and electronic R&D competencies
Financial Summary
Historical Financial Summary

Revenue

($ in millions)

<table>
<thead>
<tr>
<th>Year</th>
<th>2011</th>
<th>2012</th>
<th>2013</th>
<th>LTM Q3-14</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revenue</td>
<td>$1,075</td>
<td>$1,129</td>
<td>$1,176</td>
<td>$1,216</td>
</tr>
</tbody>
</table>

4.6% CAGR

Selected Income Statement Metrics

($ in millions)

<table>
<thead>
<tr>
<th></th>
<th>FY2012</th>
<th>FY2013</th>
<th>LTM Q3-14</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revenue</td>
<td>$1,129.4</td>
<td>$1,175.5</td>
<td>$1,215.7</td>
</tr>
<tr>
<td>Adjusted Gross Profit&lt;sup&gt;(1)&lt;/sup&gt;</td>
<td>$689.2</td>
<td>$707.1</td>
<td>$736.2</td>
</tr>
<tr>
<td>% of Revenue</td>
<td>61.0%</td>
<td>60.2%</td>
<td>60.6%</td>
</tr>
<tr>
<td>Adjusted Opex&lt;sup&gt;(1)&lt;/sup&gt;</td>
<td>$448.5</td>
<td>$476.0</td>
<td>$497.5</td>
</tr>
<tr>
<td>% of Revenue</td>
<td>39.7%</td>
<td>40.5%</td>
<td>40.9%</td>
</tr>
<tr>
<td>Adjusted EBITDA&lt;sup&gt;(1)&lt;/sup&gt;</td>
<td>$271.0</td>
<td>$264.2</td>
<td>$274.0</td>
</tr>
<tr>
<td>% of Revenue</td>
<td>24.0%</td>
<td>22.5%</td>
<td>22.5%</td>
</tr>
</tbody>
</table>

<sup>(1)</sup> Excludes impact of non-recurring costs and other adjustments as permitted by Senior Secured Credit Agreement; excludes pre-acquisition EBITDA and future cost savings related to acquisitions.

Solid revenue growth combined with company-wide productivity improving EBITDA trajectory
### September 27, 2014 Capitalization Table

($ in millions)

<table>
<thead>
<tr>
<th>Debt:</th>
<th>Rate</th>
<th>Maturity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revolver ($89.5 million available)</td>
<td>$10.0</td>
<td>L+4.75%</td>
</tr>
<tr>
<td>Term loans (3)</td>
<td>889.0</td>
<td>L+3.75%</td>
</tr>
<tr>
<td>Second priority senior secured notes (3)</td>
<td>330.0</td>
<td>8.75% (4)</td>
</tr>
<tr>
<td>New Senior unsecured notes due 2018 (3)</td>
<td>440.0</td>
<td>9.875%</td>
</tr>
<tr>
<td>Senior unsecured notes due 2018</td>
<td>300.0</td>
<td>7.75%</td>
</tr>
<tr>
<td>Senior subordinated notes due 2017</td>
<td>300.0</td>
<td>9.75%</td>
</tr>
<tr>
<td><strong>Total Debt</strong></td>
<td><strong>$ 2,269.0</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Total Contributed Equity</strong></td>
<td><strong>$ 839.5</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Total Capitalization</strong></td>
<td><strong>$ 3,108.5</strong></td>
<td></td>
</tr>
</tbody>
</table>

| Pro forma LTM Adjusted EBITDA(1)           | **$ 274.0** |            |         |
| First lien debt(2)/Adjusted EBITDA(1)      | 3.1x        |            |         |
| Secured debt(2)/Adjusted EBITDA(1)         | 4.5x        |            |         |
| Non Subordinated debt(2)/ Adjusted EBITDA(1)| 7.0x      |            |         |
| Total debt(2)/Adjusted EBITDA (1)          | 8.1x        |            |         |

| Equity/Total capitalization                | 27.0%       |            |         |

---

1) Includes net pre-acquisition EBITDA and expected future cost savings related to recent acquisitions and other adjustments as permitted by Senior Secured Credit Agreement.

2) Net of $40.8 million cash.

3) Exclusive of unamortized original issue discounts and premiums.

4) Subject to Libor Floor of 1.00%.
DJO Opportunity

Total Elective Orthopedic Surgical Market

$110M in 2014
DJO Growing 17%

$17B

MotionCare

$35M in 2014
DJO Growing 28%

$26B

Consumer Market

$10M in 2014
DJO Growing 16%

$20B
PRESCRIBE MOTION AND RETURN TO A HEALTHIER LIFE.

Business Units Overview
Bracing and Vascular – 41% of LTM Q3’14 Revenue

**Bracing Products**

- Bracing Products
- Vascular Products

**Bracing and Vascular Highlights**

- Broad range of soft goods – key to GPO penetration
- Innovative rigid bracing, walking boots and cold therapy
- Exos thermoformable bracing and splinting
- Vascular systems (DVT prophylaxis)
- Diabetic footwear
- Broad range of compression therapy garments
- #1 share in U.S. Bracing and Supports market of approximately $1.7 billion

(1) 2009 Frost & Sullivan

**Bracing and Vascular Revenue**

- ($ in millions)
- 2011: $389
- 2012: $444
- 2013: $477
- LTM Q3-14: $495

10.7% CAGR
Surgical Implant – 8% of LTM Q3’14 Revenue

- Diverse portfolio of orthopedic reconstructive joint products for knees, hips and shoulders

- Primary focus on shoulder segment with a track record of innovation – over 50% of revenue

- Niche market position with less than 1% share in total, but higher in shoulders

- U.S. market over $5 billion\(^1\)

---

(1) 2006 Frost & Sullivan.
International – 26% of LTM Q3’14 Revenue

- Continue to go-direct in countries that have shown promise
- Accelerate investment into China and India
- Continue to invest in over performing developed countries

2013 Sales Mix by Geography

- Spain, Benelux & Nordic: 4%
- Italy: 8%
- Canada: 9%
- France: 20%
- ROW: 22%
- Germany: 30%

International Net Sales

- 2011: $279
- 2012: $281
- 2013: $299
- LTM Q3-14: $322

3.5% CAGR

Excludes impact from changes in foreign currency exchange rates (constant currency) and based on average sales per day.
Recovery Sciences – 25% of LTM Q3’14 Revenue

- Home Electrotherapy - TENS Pain Management & NMES Muscle Stimulation
- Home Traction Devices
- Iontophoresis

- Promotes healing of Non-Union Bone Fractures and Spinal Repair Surgery

- Clinical Electrotherapy
- Continuous Passive Motion
- Clinical Traction Devices
- Treatment Tables

Recovery Sciences Revenue

($ in millions)

- 2011: $342
- 2012: $332
- 2013: $313
- LTM Q3-14: $302

-4.3% CAGR